Sign in

    Gene Mack

    Chief Executive Officer at Gain Therapeutics Inc
    Board
    Since January 6, 2025
    Age
    51 years
    Education
    Earned a BS in Biochemistry and an MBA in Finance from Fordham University.
    Tenure
    Joined GANX as CFO on April 8, 2024, was elevated to Interim CEO on June 25, 2024, and began serving as Chief Executive Officer on January 6, 2025.

    Also at Gain Therapeutics Inc

    GF
    Gianluca Fuggetta
    Senior Vice President Finance and Principal Financial Officer

    About

    Gene Mack has built an extensive career in the biotechnology and pharmaceutical industries, serving in senior financial roles and contributing significantly to strategic financial operations.

    At GANX, he began his tenure as CFO on April 8, 2024, swiftly transitioning to Interim CEO on June 25, 2024, and ultimately assuming the role of Chief Executive Officer on January 6, 2025, demonstrating a clear trajectory of leadership and advancement.

    With a solid educational foundation from Fordham University—holding a BS in Biochemistry and an MBA in Finance—his expertise in managing corporate finance and strategic initiatives positions him as a key contributor to the company’s ongoing growth.

    $GANX Performance Under Gene Mack

    Past Roles

    OrganizationRoleDate RangeDetails
    Gain Therapeutics, Inc. (GANX) Interim Chief Executive Officer June 25, 2024 – January 6, 2025 Held the role concurrently with CFO until his appointment as permanent CEO
    Gain Therapeutics, Inc. (GANX) Chief Financial Officer April 8, 2024 – January 6, 2025 Transitioned from CFO upon becoming permanent CEO
    Imcyse SA Chief Financial Officer October 2021 – October 2023 Biotechnology firm developing novel immunotherapeutics
    OncoC4, Inc. Chief Financial Officer September 2020 – September 2021 Company spun out after a $475M acquisition by Merck & Co.
    BiomUp, USA Inc. Chief Financial Officer May 2019 – September 2020 Focused on the development of novel hemostatic agents for surgery
    Sellas Lifesciences Group, Inc. (Nasdaq: SLS) Chief Financial Officer April 2018 – December 2018 Served during the reverse merger with Galena Biopharma
    Ascendia Pharmaceuticals and Nicox S.A. Consultant and Senior Vice President, Chief Financial Officer 2015 – March 2018 Provided advisory services for capital raising and business development
    Edge Therapeutics Senior Director, Corporate Finance 2013 – 2015 Led the company's successful IPO efforts
    Various Banking Institutions Senior Publishing Analyst 2000 – 2013 Covered the life sciences sector at firms including Gruntal & Co., Lazard, and HSBC
    Cornell University Medical College and Columbia University College of Physicians and Surgeons Researcher N/A Conducted research in biochemistry and clinical neurology (non-academic role)

    Fixed Compensation

    Data from  FY 2025
    Component NameAmountPayment ScheduleAdditional Details
    Annual Base Salary$500,000 AnnualEffective January 6, 2025 under the amended employment agreement for the permanent CEO appointment

    Performance Compensation

    Data from  FY 2025

    Annual Incentive Cash Bonus

    MetricValueNotes
    Target Bonus Percentage50% Discretionary cash bonus based on individual and company performance
    Base Salary for Calculation$500,000 Used to compute the bonus target
    Target Bonus Amount$250,000 Calculated as 50% of the annual base salary
    Performance MetricsN/ASpecific performance metrics, thresholds, and goals not provided
    Vesting ScheduleN/ANot applicable for this cash bonus
    Evaluation PeriodN/ADetails not provided
    Additional ConditionsDiscretionary payout determined by the Compensation CommitteeBased on overall evaluation of performance